Yongyue Wei1, Zhaoxi Wang2, Li Su2, Feng Chen3, Paula Tejera2, Ednan K Bajwa4, Mark M Wurfel5, Xihong Lin6, David C Christiani7. 1. Department of Environmental Health, Department of Epidemiology and Biostatistics, Ministry of Education Key Laboratory for Modern Toxicology, School of Public Health, Nanjing Medical University, Nanjing, China. 2. Department of Environmental Health, Harvard School of Public Health, Boston, MA. 3. Department of Epidemiology and Biostatistics, Ministry of Education Key Laboratory for Modern Toxicology, School of Public Health, Nanjing Medical University, Nanjing, China. 4. Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA. 5. Division of Pulmonary and Critical Care Medicine, University of Washington, Harborview Medical Center, Seattle, WA. 6. Department of Biostatistics, Harvard School of Public Health, Boston, MA. 7. Department of Environmental Health, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA. Electronic address: dchris@hsph.harvard.edu.
Abstract
BACKGROUND: Platelets are believed to be critical in pulmonary-origin ARDS as mediators of endothelial damage through their interactions with fibrinogen and multiple signal transduction pathways. A prior meta-analysis identified five loci for platelet count (PLT): BAD, LRRC16A, CD36, JMJD1C, and SLMO2. This study aims to validate the quantitative trait loci (QTLs) of PLT within BAD, LRRC16A, CD36, JMJD1C, and SLMO2 among critically ill patients and to investigate the associations of these QTLs with ARDS risk that may be mediated through PLT. METHODS: ARDS cases and at-risk control subjects were recruited from the intensive care unit of the Massachusetts General Hospital. Exome-wide genotyping data of 629 ARDS cases and 1,026 at-risk control subjects and genome-wide gene expression profiles of 18 at-risk control subjects were generated for analysis. RESULTS: Single-nucleotide polymorphism (SNP) rs7766874 within LRRC16A was a significant locus for PLT among at-risk control subjects (β = -13.00; 95% CI, -23.22 to -2.77; P = .013). This association was validated using LRRC16A gene expression data from at-risk control subjects (β = 77.03 per 1 SD increase of log2-transformed expression; 95% CI, 27.26-126.80; P = .005). Further, rs7766874 was associated with ARDS risk conditioned on PLT (OR = 0.68; 95% CI, 0.51-0.90; P = .007), interacting with PLT (OR = 1.15 per effect allele per 100 × 103/μL of PLT; 95% CI, 1.03-1.30; P = .015), and mediated through PLT (indirect OR = 1.045; 95% CI, 1.007-1.085; P = .021). CONCLUSIONS: Our findings support the role of LRRC16A in platelet formation and suggest the importance of LRRC16A in ARDS pathophysiology by interacting with, and being mediated through, platelets.
BACKGROUND: Platelets are believed to be critical in pulmonary-origin ARDS as mediators of endothelial damage through their interactions with fibrinogen and multiple signal transduction pathways. A prior meta-analysis identified five loci for platelet count (PLT): BAD, LRRC16A, CD36, JMJD1C, and SLMO2. This study aims to validate the quantitative trait loci (QTLs) of PLT within BAD, LRRC16A, CD36, JMJD1C, and SLMO2 among critically illpatients and to investigate the associations of these QTLs with ARDS risk that may be mediated through PLT. METHODS: ARDS cases and at-risk control subjects were recruited from the intensive care unit of the Massachusetts General Hospital. Exome-wide genotyping data of 629 ARDS cases and 1,026 at-risk control subjects and genome-wide gene expression profiles of 18 at-risk control subjects were generated for analysis. RESULTS: Single-nucleotide polymorphism (SNP) rs7766874 within LRRC16A was a significant locus for PLT among at-risk control subjects (β = -13.00; 95% CI, -23.22 to -2.77; P = .013). This association was validated using LRRC16A gene expression data from at-risk control subjects (β = 77.03 per 1 SD increase of log2-transformed expression; 95% CI, 27.26-126.80; P = .005). Further, rs7766874 was associated with ARDS risk conditioned on PLT (OR = 0.68; 95% CI, 0.51-0.90; P = .007), interacting with PLT (OR = 1.15 per effect allele per 100 × 103/μL of PLT; 95% CI, 1.03-1.30; P = .015), and mediated through PLT (indirect OR = 1.045; 95% CI, 1.007-1.085; P = .021). CONCLUSIONS: Our findings support the role of LRRC16A in platelet formation and suggest the importance of LRRC16A in ARDS pathophysiology by interacting with, and being mediated through, platelets.
Authors: Lei Du; Jing Zhou; Jie Zhang; Min Yan; Lina Gong; Xinhao Liu; Mi Chen; Kaiyu Tao; Nanfu Luo; Jin Liu Journal: Am J Respir Cell Mol Biol Date: 2012-06-21 Impact factor: 6.914
Authors: Carl A Anderson; Fredrik H Pettersson; Geraldine M Clarke; Lon R Cardon; Andrew P Morris; Krina T Zondervan Journal: Nat Protoc Date: 2010-08-26 Impact factor: 13.491
Authors: Li Su; Rihong Zhai; Chau-Chyun Sheu; Diana C Gallagher; Michelle N Gong; Paula Tejera; B Taylor Thompson; David C Christiani Journal: Intensive Care Med Date: 2009-03-07 Impact factor: 17.440
Authors: Chau-Chyun Sheu; Rihong Zhai; Zhaoxi Wang; Michelle N Gong; Paula Tejera; Feng Chen; Li Su; B Taylor Thompson; David C Christiani Journal: Intensive Care Med Date: 2009-06-13 Impact factor: 17.440
Authors: Jason D Christie; Mark M Wurfel; Rui Feng; Grant E O'Keefe; Jonathan Bradfield; Lorraine B Ware; David C Christiani; Carolyn S Calfee; Mitchell J Cohen; Michael Matthay; Nuala J Meyer; Cecilia Kim; Mingyao Li; Joshua Akey; Kathleen C Barnes; Jonathan Sevransky; Paul N Lanken; Addison K May; Richard Aplenc; James P Maloney; Hakon Hakonarson Journal: PLoS One Date: 2012-01-25 Impact factor: 3.240
Authors: Nicholas A Watkins; Arief Gusnanto; Bernard de Bono; Subhajyoti De; Diego Miranda-Saavedra; Debbie L Hardie; Will G J Angenent; Antony P Attwood; Peter D Ellis; Wendy Erber; Nicola S Foad; Stephen F Garner; Clare M Isacke; Jennifer Jolley; Kerstin Koch; Iain C Macaulay; Sarah L Morley; Augusto Rendon; Kate M Rice; Niall Taylor; Daphne C Thijssen-Timmer; Marloes R Tijssen; C Ellen van der Schoot; Lorenz Wernisch; Thilo Winzer; Frank Dudbridge; Christopher D Buckley; Cordelia F Langford; Sarah Teichmann; Berthold Göttgens; Willem H Ouwehand Journal: Blood Date: 2009-02-19 Impact factor: 22.113
Authors: Heather Lynn; Xiaoguang Sun; Nancy Casanova; Manuel Gonzales-Garay; Christian Bime; Joe G N Garcia Journal: Antioxid Redox Signal Date: 2019-06-18 Impact factor: 8.401
Authors: Yongyue Wei; Paula Tejera; Zhaoxi Wang; Ruyang Zhang; Feng Chen; Li Su; Xihong Lin; Ednan K Bajwa; B Taylor Thompson; David C Christiani Journal: Am J Respir Crit Care Med Date: 2017-05-15 Impact factor: 21.405
Authors: Ruyang Zhang; Zhaoxi Wang; Paula Tejera; Angela J Frank; Yongyue Wei; Li Su; Zhaozhong Zhu; Yichen Guo; Feng Chen; Ednan K Bajwa; B Taylor Thompson; David C Christiani Journal: Intensive Care Med Date: 2016-12-28 Impact factor: 17.440
Authors: Elizabeth A Middleton; Matthew T Rondina; Hansjorg Schwertz; Guy A Zimmerman Journal: Am J Respir Cell Mol Biol Date: 2018-07 Impact factor: 6.914
Authors: John P Reilly; Nuala J Meyer; Michael Gs Shashaty; Brian J Anderson; Caroline Ittner; Thomas G Dunn; Brian Lim; Caitlin Forker; Michael P Bonk; Ethan Kotloff; Rui Feng; Edward Cantu; Nilam S Mangalmurti; Carolyn S Calfee; Michael A Matthay; Carmen Mikacenic; Keith R Walley; James Russell; David C Christiani; Mark M Wurfel; Paul N Lanken; Muredach P Reilly; Jason D Christie Journal: J Clin Invest Date: 2021-01-04 Impact factor: 14.808
Authors: Chandra C Ghosh; Sascha David; Ruyang Zhang; Anthony Berghelli; Katelyn Milam; Sarah J Higgins; Jon Hunter; Aditi Mukherjee; Yongyue Wei; Mei Tran; Freeman Suber; Lester Kobzik; Kevin C Kain; Shulin Lu; Ansgar Santel; Kiichiro Yano; Prajna Guha; Daniel J Dumont; David C Christiani; Samir M Parikh Journal: Proc Natl Acad Sci U S A Date: 2016-02-16 Impact factor: 11.205